Verlingue Strengthens Its Position in Europe by Gaining a Foothold in Italy With the Acquisition From ISA of a Majority Stake in INSER
12.7.2023 11:33:00 EEST | Business Wire | Press release
Verlingue announces the acquisition of a majority stake in the insurance broker INSER, in line with its Verlingue 2024 strategic plan to create a major European, family-owned, independent insurance broker. This move to acquire a stake in the Italian market consolidates this ambition:
- Verlingue has chosen Italy as its fifth country of operations after France, the UK, Switzerland and Portugal.
- INSER is Verlingue's 7th international acquisition in 7 years
- Verlingue has become a majority shareholder in the Italian broker INSER, one of Italy's leading independent brokers
- The long-standing shareholder, ISA, remains a minority shareholder in INSER to continue to support its growth in Italy
- 160 INSER employees are joining Verlingue, whose international turnover now accounts for 35% of its total turnover.
Founded in 1979 in Trento, INSER is one of the leading independent players in the Italian insurance brokerage market. It focuses on corporate risks and public procurement. The Italian broker, which has expanded through targeted organic growth and a strategic acquisitions programme, employs nearly 160 staff in 8 offices in northern Italy (Trento, Parma, Brescia, Milan, Bergamo, Vicenza, Udine) and central Italy (Rieti).
With Italy, Verlingue is entering an important strategic market by making its seventh acquisition outside France in seven years, following on from its acquisitions in Switzerland (2016, 2017 and 2019), the UK (2018) and Portugal (2020, 2022).
With this new acquisition, the Adelaïde Group continues to execute its 2024 strategic plan with the ambition of becoming a major European, family-owned, independent insurance broker, serving increasingly international customers. Verlingue's ambition in Italy is to become a benchmark broker in the market for SMEs, mid-caps, large companies and public authorities. Verlingue will be able to rely on the current management team.
Under the terms of the partnership, Verlingue will become INSER's majority shareholder, while its long-standing shareholder, ISA, will retain a minority stake and continue to support its growth in Italy.
Giorgio Franceschi, Deputy Chairman of ISA, said: “We are delighted with this acquisition. We have found a solid and credible international partner in the family-owned Verlingue group, which will now contribute to a new phase in the development of INSER, a long-standing and important subsidiary of ISA, which we have supported in its growth and in which we will continue to be present. The partnership between Verlingue and ISA offers a great opportunity to create value for customers, employees and the region as a whole.”
Regarding the partnership, Pierpaolo Ruggeri, CEO of Inser Spa, said: “Verlingue's European project is exciting and Italy is a strategic country. This partnership will enable us to strengthen our development trajectory, both through organic growth and targeted acquisitions, in order to consolidate our positioning and offer a high-quality service to our customers.”
Benjamin Verlingue, Deputy CEO of the Adelaïde Group: “I am delighted that Adelaïde is setting up operations in Italy, Europe's fourth-largest insurance market. This opens up many positive prospects for our customers, who are becoming increasingly international.
In an industry that is consolidating, being a family-run broker with an ambitious, long-term vision means that we can offer an appealing plan to the teams who decide to join us. I'm very pleased that Inser and ISA made this choice.”
Anne-Jacques de Dinechin, Chief Executive Officer of Verlingue, said: “Our international success is based on strong local management teams in each country. With the acquisition of Inser, we are bringing on board a team of committed experts who will play a full part in our goal to become a major player in Europe.”
About Verlingue
An insurance broker specialising in business protection, Verlingue is a subsidiary of the Adelaïde Group.
Working alongside entrepreneurs, Verlingue’s goal is to harness corporate risk management and employee protection to drive its customers’ value creation and performance.
With offices in France, Portugal, Switzerland, Great Britain and Italy, and through partners in over 100 countries, Verlingue works with its customers over the long term and at all times to better understand and plan ahead for new risks in order to develop simple yet effective solutions to protect their business (corporate risk) and staff (supplementary social protection schemes and pensions).
1,350 employees, 550 of whom are based outside France
€2,350m in premiums negotiated on behalf of its customers
Operating out of 5 countries in Europe
LinkedIn/www.verlingue.fr
About Inser
Leading insurance broker providing protection for companies and public bodies. With over 40 years of experience in Italy, INSER is able to meet the specific needs of each of its customers with a team of employees capable of developing personalised solutions with the utmost care and professionalism. With 8 offices in Italy, INSER has a strong regional presence, ensuring that it is close to its customers and therefore able to generate value.
160 employees
€130m in premiums negotiated on behalf of its customers
8 locations
LinkedIn/www.inserspa.eu
About ISA
Istituto Atesino di Sviluppo Spa (ISA) is a holding company that has been operating in Trentino-Alto Adige and neighbouring regions for over 90 years. ISA's aim is to acquire stakes, mainly minority ones, by investing in diversified initiatives with the role of a patient long-term partner, with a view to creating value. Investments are selected with the utmost care and rigour, with a view to creating a sustainable development path that is attentive to social and economic growth. Through an effective network of contacts, ISA brings together private capital and financial institutions, generating opportunities for investment, growth and development.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230711157642/en/
Contact information
Press contact
Adelaïde Group – Thomas Barbelet – thomas.barbelet@verlingue.fr – +33(0)6 72 75 49 14
Epoka Agency – Lucie Fortin – lfortin@epoka.fr – +33(0)6 19 68 70 18
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
VerSprite Launches Fork and Knife: AI-Driven Threat Modeling and Adversarial Testing Built for the Speed of Modern Software27.6.2026 00:28:00 EEST | Press release
VerSprite, a global leader in risk-based threat modeling and the firm behind the PASTA (Process for Attack Simulation and Threat Analysis) methodology, today announced the general availability of Fork (www.forktm.com), a continuous application threat modeling platform, alongside Knife, an AI-led, human-on-the-loop adversarial testing platform for web applications and web API endpoints. Together, the two products operationalize a new model for product security—one where applications are securely designed, continuously modeled, and actively tested as part of the build process itself. The launch addresses a problem every security leader knows but few tools have solved: threat modeling is essential, never more so than in an AI-driven era, yet it has remained slow, manual, and anchored to frameworks designed for a different threat landscape. The problem: threat modeling matters more than ever—and most tools are stuck in 2005 For two decades, application threat modeling has leaned heavily on
Venture Global Announces Closing of $1.5 Billion Senior Secured Vessel Financing Facility26.6.2026 23:30:00 EEST | Press release
Venture Global, Inc. (NYSE: VG) announced today that its wholly-owned subsidiary, Venture Global Shipping Holdings, LLC (“VGSH”), has entered into a Credit and Guaranty Agreement providing for a senior secured term loan facility (the “Facility”) in an aggregate principal amount of up to $1,500,000,000. The Facility will mature on June 26, 2032. Deutsche Bank and ING acted as coordinating lead arrangers for the Facility. ING also serves as facility agent and security trustee. VGSH intends to use the net proceeds from the Facility for general corporate purposes, including to reimburse Venture Global LNG, Inc. for payments previously made by it or its affiliates in connection with the acquisition of nine LNG carriers, funding certain reserve accounts, and paying transaction fees and expenses. About Venture Global Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (“LNG”) with over 100 MTPA of capacity in production, construction, or development. Ven
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 21:00:00 EEST | Press release
Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solution – uses digital twin technology to identify vulnerable customers and recommend explainable next-best actions for fro
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
